Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Neurocrine Biosciences, Inc. (NBIX) vs Takeda Pharmaceutical Co. (TAK)

Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Co. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $59.2B against $14.1B — 4.2× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.6× against 28.4×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 0.66%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 7.12%) and the higher return on invested capital (15.0% vs 2.88%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 16 and Takeda Pharmaceutical Co. on 6.

Valuation

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
P/E 19.63 28.36 20.14
P/S 4.14 1.99 2.25
P/B 3.78 1.25 1.90
Price to free cash flow 16.06 8.03 16.54
EV/EBITDA 16.65 10.48 12.29
EV/Sales 4.11 2.91 2.56
Earnings yield 5.09% 3.53% (2.99%)
Free cash flow yield 6.23% 12.46% 0.00%

Profitability

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
Gross margin 97.94% 65.85% 53.94%
Operating margin 23.56% 11.61% 0.00%
Net margin 20.91% 7.12% 0.00%
Free cash flow margin 25.80% 24.74% 0.00%
Return on equity 22.09% 4.42% (0.40%)
Return on assets 15.26% 2.15% (3.32%)
Return on invested capital 15.04% 2.88% 0.00%

Growth

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 34.42% 0.66% 10.01%
EPS growth (last fiscal year) 41.95% (244.86%) —
Revenue growth, 5-year CAGR 22.29% (0.21%) 6.74%
Net income growth, 5-year CAGR 3.28% 0.00% 0.00%

Health

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.65 0.05
Current ratio 1.87 1.14 2.31
Net debt to EBITDA (2.33) 5.84 0.85

Dividend

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
Dividend yield — 4.52% 1.70%
Payout ratio 0.00 0.50 0.00

Size

Metric NBIX TAK Drug Manufacturers Specialty & Generic median
Market cap 14.12b 59.16b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack